{'fraction_non_alphanumeric': 0.013927576601671309, 'fraction_numerical': 0.0064995357474466105, 'mean_word_length': 5.267441860465116, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Nuclear VCP acts as a tumor promoting factor for oral squamous cell carcinoma

The objective of this study is to characterize the oncogenic role of a recently identified cancer‐associated gene called VCP (also known as p97 or CDC48) in oral cancer and its clinical implications for developing new molecular diagnostics and therapy. Based on a genomewide study, this gene was found located at the 9p13 amplicon in oral squamous cell carcinomas (OSCC). In addition, VCP gene has been reported highly upregulated in a variety of tumor samples. Thus, it is believed that VCP gene plays a crucial role in cancer development and progression. Our preliminary data indicate that VCP amplification correlates with nuclear localization of its protein and poor clinical outcome, suggesting VCP partners with several nuclear proteins to form a functional complex that may provide growth advantages for oncogenic signaling and cancer aggressiveness. Blocking the assembly of nuclear VCP complex could be a potential therapeutic approach to treat oral cancer patients with VCP amplification.